- Home
- LPCN vs AKTX Comparison
LPCN vs AKTX Comparison
Compare LPCN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- AKTX
- Stock Information
- Founded
- LPCN 1997
- AKTX N/A
- Country
- LPCN United States
- AKTX United States
- Employees
- LPCN N/A
- AKTX N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- AKTX Health Care
- Exchange
- LPCN Nasdaq
- AKTX Nasdaq
- Market Cap
- LPCN 36.8M
- AKTX 37.4M
- IPO Year
- LPCN N/A
- AKTX N/A
- Fundamental
- Price
- LPCN $5.46
- AKTX $2.13
- Analyst Decision
- LPCN Strong Buy
- AKTX
- Analyst Count
- LPCN 1
- AKTX 0
- Target Price
- LPCN $10.00
- AKTX N/A
- AVG Volume (30 Days)
- LPCN 23.4K
- AKTX 21.6K
- Earning Date
- LPCN 11-06-2024
- AKTX 11-19-2024
- Dividend Yield
- LPCN N/A
- AKTX N/A
- EPS Growth
- LPCN N/A
- AKTX N/A
- EPS
- LPCN N/A
- AKTX N/A
- Revenue
- LPCN $4,800,930.00
- AKTX N/A
- Revenue This Year
- LPCN N/A
- AKTX N/A
- Revenue Next Year
- LPCN N/A
- AKTX N/A
- P/E Ratio
- LPCN N/A
- AKTX N/A
- Revenue Growth
- LPCN 8630.55
- AKTX N/A
- 52 Week Low
- LPCN $2.31
- AKTX $1.08
- 52 Week High
- LPCN $11.79
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- LPCN 61.75
- AKTX 22.25
- Support Level
- LPCN $4.89
- AKTX $2.20
- Resistance Level
- LPCN $5.85
- AKTX $2.49
- Average True Range (ATR)
- LPCN 0.38
- AKTX 0.35
- MACD
- LPCN 0.04
- AKTX -0.06
- Stochastic Oscillator
- LPCN 64.83
- AKTX 1.92
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).